GammaCan International, Inc. Files Additional Patent Applications Covering The Treatment Of Malignant Melanoma And Colorectal Cancer With The United States Patent And Trademark Office

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International Inc.(OTCBB:GCAN), a developer of immunotherapies for cancer and other diseases, today announced that the Company filed two Continuations in Part (CIP) with the U.S. Patent and Trademark Office.